8 capital gives TRIP a buy rating with $.35 price target Red Light Holland (link for entire article at bottom)
Current price: $0.23
Target price: $0.35
Red Light Holland’s aggressive acquisition strategy and foothold in the European recreational psilocybin retail market give it a competitive advantage.
“The Company’s Netherlands operations give it access to other low-barrier jurisdictions in Europe (e.g. Portugal, Czech Republic, etc). It has also established access to its iMicrodose kits for patients in Brazil, on a prescribed basis. Furthermore, RLH recently acquired Mera Life Sciences, a Caribbean-based operator where local regulations allow for the Company to work with naturally-derived psychedelic compounds including psilocybin, ibogaine, mescaline, dimethyltryptamine, and many others. RLH’s revenue-generating operations centered around production, sale, and distribution of psychedelic substances, stand to benefit from such broad access to psychedelic compounds as it works to expand its offerings, and its reach across more jurisdictions.”
https://www.benzinga.com/markets/cannabis/21/10/23016304/6-psychedelic-stocks-with-buy-rating-why-are-they-good-investments